ClinicalTrials.gg
TerminatedNCT02013765Updated Sep 25, 2014Results posted

A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

A Phase 2 interventional study of trastuzumab in Urinary Tract Cancer, sponsored by Hoffmann-La Roche. Terminated at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-25.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial was terminated prematurely because of recruitment difficulties.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Urologic Neoplasms with a site in Germany — 2 open to participants now, 3 under way, none of them phase 3. Urologic Neoplasms · Germany.

Enrollment
10th of 10
5 · median 200
Started
2001
with 1 other
Phase 2
7 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
3 of 13
Hoffmann-La Roche

Among the 13 studies in Urologic Neoplasms with a site in Germany, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 2, and was the 4th registered.

Urologic Neoplasms

155 studies on the registry are indexed under Urologic Neoplasms; 40 are open to participants now.

Browse Urologic Neoplasms studies →

Open to participants now

2 of the 13 studies in Urologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 30 Urologic Neoplasms studies recruiting now, 24 (80%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Urologic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of intravenous Herceptin in patients with metastatic urothelial cancer with disease progression during platinum-based chemotherapy. The anticipated time on study treatment is until disease progression.

03

Conditions studied

  • Urinary Tract Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients >=18 years of age;
  • urothelial cancer;
  • disease progression during or after 1 prior platinum-based chemotherapy;
  • ;
  • overexpression (IHC [2+] or [3+]).

Exclusion criteria

Exclusion Criteria:

  • concomitant chemotherapy or immunotherapy;
  • active or uncontrolled infection;
  • solely ;
  • cardiac disease, advanced pulmonary disease or severe dyspnoea;
  • co-existing diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Trastuzumab Monotherapy

    Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.

    Drug: trastuzumab

Interventions

  • Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) - Percentage of Participants With an Event

    PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause.

    Time frame: Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment

  2. Progression-Free Survival - Time to Event

    The median time, in months, from the first study drug treatment to a PFS event.

    Time frame: Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment

  3. Percentage of Participants Progression Free at 12 and 24 Months

    Time frame: Months 12 and 24

Secondary outcomes

  1. Overall Survival (OS) - Percentage of Participants With an Event

    OS was defined as the time from the start of study treatment to date of death due to any cause.

    Time frame: Screening, every 4 weeks during treatment (up to 37 weeks), at end of treatment, and every 3 months thereafter

  2. Overall Survival - Time to Event

    The median time, in months, from the start of study treatment to an OS event.

    Time frame: Screening, every 4 weeks during treatment (up to 37 weeks), at end of treatment, and every 3 months thereafter

  3. Percentage of Participants Surviving at 12 and 24 Months

    Time frame: Months 12 and 24

  4. Percentage of Participants by Best Overall Response to Treatment

    Per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Complete response (CR) was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal \[(short axis less than (\<)10 millimeters (mm)\]. No new lesions. Partial response (PR) was defined as greater than or equal to (≥)30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD) was defined as not qualifying for CR, PR, or progressive disease (PD).

    Time frame: Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment

07

Results

Posted Sep 25, 2014

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab Monotherapy
Started5
Completed4
Not completed1
Withdrew: Trial was terminated by sponsor1

Outcome measures

PrimaryProgression-Free Survival (PFS) - Percentage of Participants With an Event

PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause.

Time frame:
Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment
Reported as:
Number · percentage of participants
Progression-Free Survival (PFS) - Percentage of Participants With an Event
percentage of participantsTrastuzumab Monotherapy
Progression-Free Survival (PFS) - Percentage of Participants With an Event80.0
SecondaryOverall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the start of study treatment to date of death due to any cause.

Time frame:
Screening, every 4 weeks during treatment (up to 37 weeks), at end of treatment, and every 3 months thereafter
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
percentage of participantsTrastuzumab Monotherapy
Overall Survival (OS) - Percentage of Participants With an Event80.0
SecondaryOverall Survival - Time to Event

The median time, in months, from the start of study treatment to an OS event.

Time frame:
Screening, every 4 weeks during treatment (up to 37 weeks), at end of treatment, and every 3 months thereafter
Reported as:
Median · months
Overall Survival - Time to Event
monthsTrastuzumab Monotherapy
Overall Survival - Time to Event14.7 (2.5 to NA)
SecondaryPercentage of Participants Surviving at 12 and 24 Months
Time frame:
Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Surviving at 12 and 24 Months
percentage of participantsTrastuzumab Monotherapy
12 Months60.0 (12.6 to 88.2)
24 Months20.0 (0.8 to 58.2)
PrimaryProgression-Free Survival - Time to Event

The median time, in months, from the first study drug treatment to a PFS event.

Time frame:
Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment
Reported as:
Median · months
Progression-Free Survival - Time to Event
monthsTrastuzumab Monotherapy
Progression-Free Survival - Time to Event2.5 (0.7 to NA)
SecondaryPercentage of Participants by Best Overall Response to Treatment

Per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Complete response (CR) was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal \[(short axis less than (\<)10 millimeters (mm)\]. No new lesions. Partial response (PR) was defined as greater than or equal to (≥)30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD) was defined as not qualifying for CR, PR, or progressive disease (PD).

Time frame:
Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment
Reported as:
Number · percentage of participants
Percentage of Participants by Best Overall Response to Treatment
percentage of participantsTrastuzumab Monotherapy
SD20.0
PD80.0
SD/PD100.0
PrimaryPercentage of Participants Progression Free at 12 and 24 Months
Time frame:
Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Progression Free at 12 and 24 Months
percentage of participantsTrastuzumab Monotherapy
12 Months20.0 (0.8 to 58.2)
24 Months20.0 (0.8 to 58.2)

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were recorded from study start to 30 days after the last dose of study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Monotherapy—2/5 (40%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventTrastuzumab Monotherapy
Pain - stomachGeneral disorders1/5
Obstruction - GURenal and urinary disorders1/5
DyspnoeaRespiratory, thoracic and mediastinal disorders1/5
Most frequent other events
Most frequent other events
EventTrastuzumab Monotherapy
Pain - extremity, limbGeneral disorders1/5
Pain - headacheGeneral disorders1/5
DyspnoeaRespiratory, thoracic and mediastinal disorders1/5
HypertensionCardiac disorders1/5
Constitutional symptoms - other (not specified)General disorders1/5
DiarrhoeaGastrointestinal disorders1/5
Infection - other (not specified)Infections and infestations1/5
Infection with unknown absolute neutrophil count (ANC)Infections and infestations1/5
Metabolic/laboratory - other (not specified)Metabolism and nutrition disorders1/5

Baseline characteristics

Full analysis set (FAS) includes all participants who received study treatment.

Age, Continuous
Age, Continuous(years)Trastuzumab Monotherapy
Mean67.4 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Monotherapy
Female0
Male5
08

Study locations

7 sites
  • Aschersleben, 06449, Germany
  • Dessau, 06846, Germany
  • Fulda, 36043, Germany
  • Leipzig, 04103, Germany
  • Leipzig, 04277, Germany
  • Marburg, 35043, Germany
  • Weiden, 92637, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Dec 17, 2013
Start
Jan 2001
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Sep 25, 2014
Last update
Sep 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02013765
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Jan 2001
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Sep 25, 2014
Last update
Sep 25, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion